IPL344 for ALS
IPL344 has entered a phase 1/2a, open-label, dose-escalating study with amyotrophic lateral sclerosis (ALS) patients to assess the safety, tolerability and pharmacokinetics of intravenously administrated IPL344. By the end of this part of the study, the participants continue to an open-label, phase 2a study. The study takes place in the ALS Clinic of the Neurology Department of the Hadassah Medical Center in Jerusalem, Israel. Immunity Pharma prepares for a global multicenter phase 2b/3 trial.
Promising Interim Results of IPL's Phase 1/2a Study with IPL344 in ALS